PortalPublikationenBosutinib versus imatinib in newly diagnosed chronic-phase c...

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Standard

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. / Cortes, Jorge E; Kim, Dong-Wook; Kantarjian, Hagop M; Brümmendorf, Tim; Dyagil, Irina; Griskevicius, Laimonas; Malhotra, Hemant; Powell, Christine; Gogat, Karïn; Countouriotis, Athena M; Gambacorti-Passerini, Carlo.

in: J CLIN ONCOL, Jahrgang 30, Nr. 28, 28, 2012, S. 3486-3492.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Cortes, JE, Kim, D-W, Kantarjian, HM, Brümmendorf, T, Dyagil, I, Griskevicius, L, Malhotra, H, Powell, C, Gogat, K, Countouriotis, AM & Gambacorti-Passerini, C 2012, 'Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.', J CLIN ONCOL, Jg. 30, Nr. 28, 28, S. 3486-3492. <http://www.ncbi.nlm.nih.gov/pubmed/22949154?dopt=Citation>

APA

Cortes, J. E., Kim, D-W., Kantarjian, H. M., Brümmendorf, T., Dyagil, I., Griskevicius, L., Malhotra, H., Powell, C., Gogat, K., Countouriotis, A. M., & Gambacorti-Passerini, C. (2012). Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J CLIN ONCOL, 30(28), 3486-3492. [28]. http://www.ncbi.nlm.nih.gov/pubmed/22949154?dopt=Citation

Vancouver

Cortes JE, Kim D-W, Kantarjian HM, Brümmendorf T, Dyagil I, Griskevicius L et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J CLIN ONCOL. 2012;30(28):3486-3492. 28.

Bibtex

@article{6955758452d84f3cbec9e4cdf2ab5f80,
title = "Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.",
abstract = "Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid leukemia (CML).",
keywords = "Adult, Humans, Male, Aged, Middle Aged, Aged, 80 and over, Adolescent, Young Adult, Piperazines/adverse effects/*therapeutic use, Pyrimidines/adverse effects/*therapeutic use, Antineoplastic Agents/adverse effects/*therapeutic use, Aniline Compounds/adverse effects/*therapeutic use, Leukemia, Myeloid, Chronic-Phase/*drug therapy, Nitriles/adverse effects/*therapeutic use, Protein-Tyrosine Kinases/adverse effects/*therapeutic use, Quinolines/adverse effects/*therapeutic use, Adult, Humans, Male, Aged, Middle Aged, Aged, 80 and over, Adolescent, Young Adult, Piperazines/adverse effects/*therapeutic use, Pyrimidines/adverse effects/*therapeutic use, Antineoplastic Agents/adverse effects/*therapeutic use, Aniline Compounds/adverse effects/*therapeutic use, Leukemia, Myeloid, Chronic-Phase/*drug therapy, Nitriles/adverse effects/*therapeutic use, Protein-Tyrosine Kinases/adverse effects/*therapeutic use, Quinolines/adverse effects/*therapeutic use",
author = "Cortes, {Jorge E} and Dong-Wook Kim and Kantarjian, {Hagop M} and Tim Br{\"u}mmendorf and Irina Dyagil and Laimonas Griskevicius and Hemant Malhotra and Christine Powell and Kar{\"i}n Gogat and Countouriotis, {Athena M} and Carlo Gambacorti-Passerini",
year = "2012",
language = "English",
volume = "30",
pages = "3486--3492",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "28",

}

RIS

TY - JOUR

T1 - Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

AU - Cortes, Jorge E

AU - Kim, Dong-Wook

AU - Kantarjian, Hagop M

AU - Brümmendorf, Tim

AU - Dyagil, Irina

AU - Griskevicius, Laimonas

AU - Malhotra, Hemant

AU - Powell, Christine

AU - Gogat, Karïn

AU - Countouriotis, Athena M

AU - Gambacorti-Passerini, Carlo

PY - 2012

Y1 - 2012

N2 - Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid leukemia (CML).

AB - Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid leukemia (CML).

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Middle Aged

KW - Aged, 80 and over

KW - Adolescent

KW - Young Adult

KW - Piperazines/adverse effects/therapeutic use

KW - Pyrimidines/adverse effects/therapeutic use

KW - Antineoplastic Agents/adverse effects/therapeutic use

KW - Aniline Compounds/adverse effects/therapeutic use

KW - Leukemia, Myeloid, Chronic-Phase/drug therapy

KW - Nitriles/adverse effects/therapeutic use

KW - Protein-Tyrosine Kinases/adverse effects/therapeutic use

KW - Quinolines/adverse effects/therapeutic use

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Middle Aged

KW - Aged, 80 and over

KW - Adolescent

KW - Young Adult

KW - Piperazines/adverse effects/therapeutic use

KW - Pyrimidines/adverse effects/therapeutic use

KW - Antineoplastic Agents/adverse effects/therapeutic use

KW - Aniline Compounds/adverse effects/therapeutic use

KW - Leukemia, Myeloid, Chronic-Phase/drug therapy

KW - Nitriles/adverse effects/therapeutic use

KW - Protein-Tyrosine Kinases/adverse effects/therapeutic use

KW - Quinolines/adverse effects/therapeutic use

M3 - SCORING: Journal article

VL - 30

SP - 3486

EP - 3492

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 28

M1 - 28

ER -